All Posts | Links Medicus - Free Medical News & Perspective

RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19

7 Mar, 2021 | 20:15h | UTC

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Commentary on Twitter

The PRINCIPLE trial publishes its first peer reviewed paper, showing results from the study of azithromycin as a treatment for Covid-19 in the community. @TheLancet #UrgentCovidResearch #PRINCIPLETrial
👉https://t.co/qKRI5PVpQk pic.twitter.com/BVQztDSvSC

— OxPrimaryCareSci (@OxPrimaryCare) March 5, 2021

WHO: The effects of virus variants on COVID-19 vaccines

7 Mar, 2021 | 20:09h | UTC

The effects of virus variants on COVID-19 vaccines – World Health Organization

Mask mandates and restaurant restrictions tied to fewer Covid-19 illnesses and deaths, CDC study says

7 Mar, 2021 | 20:07h | UTC

Mask mandates and restaurant restrictions tied to fewer Covid-19 illnesses and deaths, CDC study says – CNN

Original study: Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter

A new @CDCMMWR finds that state-issued mask requirements are associated with the slowing of #COVID19 cases and deaths. Wearing a well-fitting mask consistently and correctly is one of the best ways we can protect ourselves and each other. Learn more: https://t.co/8YtmIMPMY0. pic.twitter.com/BLb56SGb2g

— CDC (@CDCgov) March 5, 2021

[Preprint] Genomics and epidemiology of a novel SARS-CoV-2 lineage P.1 – “P.1 may be 1.4–2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages”

7 Mar, 2021 | 20:05h | UTC

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil – medRxiv

Commentary: Brazil variant can reinfect virus survivors; COVID-19 vaccine antibodies pass into breast milk – Reuters

[Preprint] SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

7 Mar, 2021 | 19:53h | UTC

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization – bioRxiv

Commentary: Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization – News Medical

[Medicine based on data leaks…] Oxford study indicates AstraZeneca vaccine is effective against SARS-CoV-2 Lineage P.1

7 Mar, 2021 | 19:48h | UTC

Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says – Reuters

Commentary on Twitter

https://twitter.com/hildabast/status/1368010132781600773

[Preprint] Preliminary study shows Sinovac vaccine may not trigger sufficient antibody response to SARS-CoV-2 Lineage P.1

7 Mar, 2021 | 19:49h | UTC

Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination – The Lancet

Commentary: Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study – Reuters

Commentary on Twitter

1) In a preprint (to the Lancet), the new Brazilian #SARSCoV2 variant P.1. was found to reduce the neutralizing ability of post-COVID-19 antibodies by about 6-fold, compared with the B lineage.https://t.co/obYmktWFXr pic.twitter.com/3IPiUjHB3l

— Jonathan Cedernaes (@JCedernaes) March 2, 2021

Diagnosis of non-consensus transient ischemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis

7 Mar, 2021 | 19:32h | UTC

Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis – The Lancet

Commentary on Twitter

Some patients present with symptoms that are considered not definitive for TIA (isolated dysarthria, vertigo, etc). Are these patients at risk for later stroke? Fascinating results in @TheLancet from the Oxford Vascular Study@ESOstroke @WorldStrokeOrg https://t.co/l0tJXseE3Y

— Seemant Chaturvedi (@ChaturvediNeuro) March 5, 2021

[Preprint] Increased risk of hospitalization associated with infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark

7 Mar, 2021 | 19:46h | UTC

Increased Risk of Hospitalisation Associated with Infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark – The Lancet

Commentary on Twitter (thread – click for more)

📍~64% MORE SEVERE—The already more contagious #B117 variant from 🇬🇧 is now found to increase risk of #COVID19 hospitalization by 64% versus other strains, says Denmark’s 🇩🇰 CDC. Denmark sequences every cases—their data is the best, & now most worrisome.🧵 https://t.co/F6w2JYEUnM pic.twitter.com/mngJoTBZtl

— Eric Feigl-Ding (@DrEricDing) March 4, 2021

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

7 Mar, 2021 | 19:43h | UTC

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines – Cell Host & Microbiome

Commentary on Twitter (thread – click for more)

Very good and important new data on the UK variant and vaccine response
"B.1.1.7 is not a neutralization escape variant of concern for COVID-19 vaccines"
"B.1.1.7 is unlikely to increase the risk of SARS-CoV-2 re-infection"https://t.co/DWzwBUDwY3 @cellhostmicrobe pic.twitter.com/iQv7mL9MHq

— Eric Topol (@EricTopol) March 4, 2021

New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer

7 Mar, 2021 | 19:28h | UTC

News Release: New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer – World Health Organization

Technical Document: Technical specifications of radiotherapy equipment for cancer treatment

🆕 guidance on the procurement of radiotherapy equipment released today in collaboration with @iaeaorg, aims to improve access to this life-saving #cancer treatment option that is still lacking in many parts of the world 🌎🌍🌏

👉 https://t.co/fnR0q3DDMq pic.twitter.com/21SHSaQGy7

— World Health Organization (WHO) (@WHO) March 5, 2021

Study: Cancer patients benefit from using automated device to manage their symptoms

7 Mar, 2021 | 19:21h | UTC

Cancer patients benefit from using automated device to manage their symptoms – News Medical / University of Leeds

Original study: Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy – Journal of Clinical Oncology

Editorial: Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment – Journal of Clinical Oncology

Treatment effects in randomized trials using routinely collected data for outcome assessment versus traditional trials: meta-research study

7 Mar, 2021 | 19:18h | UTC

Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study – The BMJ

WHO Guidance: Management of people affected by lymphatic filariasis

7 Mar, 2021 | 19:26h | UTC

News release: WHO publishes materials that aim to provide high-quality care to people affected by lymphatic filariasis – World Health Organization

Guidance: Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers, 2nd ed. – World Health Organization

Conversion of Propranolol to Carvedilol in patients with cirrhosis and ascites: Small randomized, open label study suggests improvement in outcomes

7 Mar, 2021 | 19:08h | UTC

Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites – Clinical Gastroenterology (link to abstract – $ for full-text)

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

7 Mar, 2021 | 19:11h | UTC

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentary: Published 2-Year Partner 3 Data Shed New Light on TAVI, SAVR Choice in Low-risk Patients – TCTMD

Quantitatively evaluating the cross-sectoral and One Health impact of interventions: A scoping review and case study of antimicrobial resistance

7 Mar, 2021 | 19:10h | UTC

Quantitatively evaluating the cross-sectoral and One Health impact of interventions: A scoping review and case study of antimicrobial resistance – One Health

Infographic: Economic evaluations of One-Health interventions: an antimicrobial resistance case study

Commentary on Twitter

An exciting paper by @nichola_naylor sets out a new way to quantitatively evaluate the #OneHealth impact of interventions, using #AMR as a case study.

Read the full paper ➡️ https://t.co/IPVoa0lTMh
Download our infographic ➡️ https://t.co/vjtjgwkkOX pic.twitter.com/lzAqbcWern

— LSHTM AMR Centre (@LSHTM_AMR) March 1, 2021

RCT: Biologic mesh implantation is associated with serious abdominal wall complications in patients undergoing emergency abdominal surgery

7 Mar, 2021 | 19:07h | UTC

Biologic mesh implantation is associated with serious abdominal wall complications in patients undergoing emergency abdominal surgery: A randomized-controlled clinical trial – Trauma & Acute Care Surgery (link to abstract – $ for full-text)

RCT: Rituximab vs. tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis

7 Mar, 2021 | 19:06h | UTC

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial – The Lancet

Commentary: Precision medicine in rheumatology: are we getting closer? – The Lancet

Commentary on Twitter

For patients with rheumatoid #arthritis and low or absent B-cell lineage expression signature in synovial tissue, tocilizumab is more effective than rituximab, suggests the first biopsy-driven trial. Read the results in full: https://t.co/XjzOqeBwdc pic.twitter.com/hODUwDy8BP

— The Lancet (@TheLancet) January 26, 2021

Randomized, crossover trial: A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes

7 Mar, 2021 | 19:03h | UTC

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

In a crossover trial of adolescents and young adults with type 1 #diabetes, daytime hyperglycaemia was reduced without increasing hypoglycaemia using the advanced hybrid closed-loop system compared with the 670G system. Read the study: https://t.co/WtU9O3uGkb pic.twitter.com/bf8HV6scKQ

— The Lancet (@TheLancet) January 18, 2021